Journal List > Endocrinol Metab > v.26(2) > 1085872

TOOLS
Yi, Bae, Kim, Park, Kim, Park, Choi, Park, Lee, Lee, Kim, Kim, Choi, and Kim: The Association between Type 2 Diabetes Mellitus and Colorectal Cancer
Original Article
Endocrinology and Metabolism

Endocrinology and Metabolism 2011; 26(2): 126-132.

Published online: 30 June 2011

DOI: https://doi.org/10.3803/EnM.2011.26.2.126

The Association between Type 2 Diabetes Mellitus and Colorectal Cancer

Byeong Do Yi, Young Pil Bae, Bong Gun Kim, Jong Wha Park, Dong Hyun Kim, Ja Young Park, Seong Ho Choi, Hee Seung Park, Jae Seung Lee, Chang Won Lee, Sang Soo Kim1, Bo Hyun Kim1, Moon Ki Choi1, In Joo Kim1

Department of Internal Medicine, Busan St. Mary's Medical Center, Busan, Korea.

1Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea.

Corresponding author: Chang Won Lee. Department of Internal Medicine, Busan St. Mary's Medical Center, 538-41 Yongho-dong, Nam-gu, Busan 608-838, Korea. Tel: +82-51-933-7235, Fax: +82-51-932-8600, koje94@hanmail.net

Received 16 August 2010       Accepted 3 January 2011

Copyright © 2011 Korean Endocrine Society

Abstract

Background

There is a close connection between type 2 diabetes mellitus and the risk of cancers and related mortality. The principal objective of the present study was to explore the association between type 2 diabetes and colorectal cancer.

Methods

We retrospectively compared 1111 subjects (age ≥ 30 years) who were subjected to colonoscopies between June 2006 and June 2009. We evaluated the anthropometric data, presenting symptoms and signs, history of diabetes, laboratory data, colonoscopy findings and biopsy results. We analyzed the correlation between colorectal cancer and influencing factors, and compared the incidence rates of colorectal cancer in the type 2 diabetes and control groups.

Results

Four hundreds and seven of the subjects had diabetes mellitus. The incidence of colorectal cancer was increased significantly in type 2 diabetes relative to the control group (7.4% vs. 3.4%, P < 0.05). Colorectal cancer was correlated significantly with age, type 2 diabetes, constipation, anemia, and gastrointestinal symptoms. Following logistic regression analysis, age and constipation were associated significantly with colorectal cancer. In the age below 65 years subgroup, the incidence of colorectal cancer was increased significantly in the type 2 diabetes group relative to the control group.

Conclusion

Type 2 diabetes was associated with increased colorectal cancer risk. This association was more definite in the subjects younger than 65 years.

Keywords: Diabetes mellitus type 2, Colonoscopy, Colorectal cancer

Figures and Tables

Table 1
Baseline characteristics in study subject (1)
enm-26-126-i001

Data are expressed in the means ± SD, P-values < 0.05 were considered sig-nificant.

Adenomatous polyp, colon adenomatous polyp; BMI, body mass index; GI sym-ptom, gastrointestinal symptom.

Table 2
Baseline characteristics in study subject (2)
enm-26-126-i002

BMI, body mass index; GI symptom, gastrointestinal symptom.

Table 3
The correlation between colorectal cancer and variables
enm-26-126-i003

*The multiple logistic regression analysis model (enter method).

GI symptom, gastrointestinal symptom.

Table 4
The prevalence of colorectal cancer according to diabetes and age
enm-26-126-i004

Odds ratio (95% confidence interval). N is number.

*Cochran-Mantel-Haenszel Chi-square test. ≤ 65, ≤ 65 year old; > 65, > 65 year old; cancer (-), no colorectal cancer; cancer (+), colorectal cancer.

Table 5
The correlation between colorectal cancer and variables in type 2 diabetes
enm-26-126-i005

Data are expressed in the means ± SD.

Alcohol, current drinking; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; DBP, diastolic blood pressure; DM, diabetes mellitus; γ-GTP, gamma-glutamyltransfesrase; HDL-cholesterol, high density lipoprotein cholesterol; hs-CRP, high sensitive C-reactive protein; HOMA-IR, home-ostasis model assessment of insulin resistance; LDL-cholesterol, low density lipoprotein cholesterol; Smoking, current smoker; SBP, systolic blood pressure.

References

1. Engelgau MM, Geiss LS, Saaddine JB, Boyle JP, Benjamin SM, Gregg EW, Tierney EF, Rios-Burrows N, Mokdad AH, Ford ES, Imperatore G, Narayan KM. The evolving diabetes burden in the United States. Ann Intern Med. 2004. 140:945–950.
2. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics, 2005. CA Cancer J Clin. 2005. 55:10–30.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005. 55:74–108.
4. Kim SG, Choi DS. The present state of diabetes mellitus in Korea. J Korean Med Assoc. 2008. 51:791–798.
5. Roper NA, Bilous RW, Kelly WF, Unwin NC, Connolly VM. Cause-specific mortality in a population with diabetes: South Tees Diabetes Mortality Study. Diabetes Care. 2002. 25:43–48.
6. Park SK, Park MK, Suk JH, Kim MK, Kim YK, Kim IJ, Kang YH, Lee KJ, Lee HS, Lee CW, Kim BH, Lee KI, Kim MK, Kim DK. Cause-of-death trends for diabetes mellitus over 10 years. Korean Diabetes J. 2009. 33:65–72.
7. Wolf I, Sadetzki S, Catane R, Karasik A, Kaufman B. Diabetes mellitus and breast cancer. Lancet Oncol. 2005. 6:103–111.
8. Renehan AG, Shalet SM. Diabetes, insulin therapy, and colorectal cancer. BMJ. 2005. 330:551–552.
9. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol. 2004. 159:1160–1167.
10. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer. 2005. 92:2076–2083.
11. Larsson SC, Orsini N, Brismar K, Wolk A. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia. 2006. 49:2819–2823.
12. Potter JD, Slattery ML, Bostick RM, Gapstur SM. Colon cancer: a review of the epidemiology. Epidemiol Rev. 1993. 15:499–545.
13. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009. 59:225–249.
14. Shin HR, Jung KW, Won YJ, Park JG. 2002 annual report of the Korea Central Cancer Registry: based on registered data from 139 hospitals. Cancer Res Treat. 2004. 36:103–114.
15. Greenwald P. Colon cancer overview. Cancer. 1992. 70:1206–1215.
16. Fuchs CS, Giovannucci EL, Colditz GA, Hunter DJ, Speizer FE, Willett WC. A prospective study of family history and the risk of colorectal cancer. N Engl J Med. 1994. 331:1669–1674.
17. Frezza EE, Wachtel MS, Chiriva-Internati M. Influence of obesity on the risk of developing colon cancer. Gut. 2006. 55:285–291.
18. Kim SJ, Choi CH, Moon HJ, Mun JS, Lee HW, Kim HJ, Do JH, Chang SK. Diabetes mellitus and the risk of colorectal adenoma. Intest Res. 2008. 6:50–55.
19. National Cancer Center. The Korean Society of Coloproctology. Recommendations of colorectal cancer examination. 1998.
20. Will JC, Galuska DA, Vinicor F, Calle EE. Colorectal cancer: another complication of diabetes mellitus? Am J Epidemiol. 1998. 147:816–825.
21. Limburg PJ, Anderson KE, Johnson TW, Jacobs DR Jr, Lazovich D, Hong CP, Nicodemus KK, Folsom AR. Diabetes mellitus and subsite-specific colorectal cancer risks in the Iowa Women's Health Study. Cancer Epidemiol Biomarkers Prev. 2005. 14:133–137.
22. Limburg PJ, Vierkant RA, Fredericksen ZS, Leibson CL, Rizza RA, Gupta AK, Ahlquist DA, Melton LJ 3rd, Sellers TA, Cerhan JR. Clinically confirmed type 2 diabetes mellitus and colorectal cancer risk: a population-based, retrospective cohort study. Am J Gastroenterol. 2006. 101:1872–1879.
23. Sturmer T, Buring JE, Lee IM, Gaziano JM, Glynn RJ. Metabolic abnormalities and risk for colorectal cancer in the physicians' health study. Cancer Epidemiol Biomarkers Prev. 2006. 15:2391–2397.
24. Vinikoor LC, Long MD, Keku TO, Martin CF, Galanko JA, Sandler RS. The association between diabetes, insulin use, and colorectal cancer among Whites and African Americans. Cancer Epidemiol Biomarkers Prev. 2009. 18:1239–1242.
25. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst. 2005. 97:1679–1687.
26. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985. 28:412–419.
27. Hamilton W, Lancashire R, Sharp D, Peters TJ, Cheng K, Marshall T. The risk of colorectal cancer with symptoms at different ages and between the sexes: a case-control study. BMC Med. 2009. 7:17.
28. Moghaddam AA, Woodward M, Huxley R. Obesity and risk of colorectal cancer: a meta-analysis of 31 studies with 70,000 events. Cancer Epidemiol Biomarkers Prev. 2007. 16:2533–2547.
29. Suehiro T, Matsumata T, Shikada Y, Sugimachi K. Hyperinsulinemia in patients with colorectal cancer. Hepatogastroenterology. 2005. 52:76–78.
30. Godsland IF. Insulin resistance and hyperinsulinaemia in the development and progression of cancer. Clin Sci (Lond). 2010. 118:315–332.
31. Komninou D, Ayonote A, Richie JP Jr, Rigas B. Insulin resistance and its contribution to colon carcinogenesis. Exp Biol Med (Maywood). 2003. 228:396–405.
32. Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst. 2002. 94:972–980.
33. Trevisan M, Liu J, Muti P, Misciagna G, Menotti A, Fucci F. Markers of insulin resistance and colorectal cancer mortality. Cancer Epidemiol Biomarkers Prev. 2001. 10:937–941.
34. Colangelo LA, Gapstur SM, Gann PH, Dyer AR, Liu K. Colorectal cancer mortality and factors related to the insulin resistance syndrome. Cancer Epidemiol Biomarkers Prev. 2002. 11:385–391.
35. Saydah SH, Platz EA, Rifai N, Pollak MN, Brancati FL, Helzlsouer KJ. Association of markers of insulin and glucose control with subsequent colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2003. 12:412–418.
36. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006. 29:254–258.
37. Monami M, Lamanna C, Balzi D, Marchionni N, Mannucci E. Sulphonylureas and cancer: a case-control study. Acta Diabetol. 2009. 46:279–284.
38. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med. 2007. 356:2131–2142.
39. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, Low M, Greenson JK, Rennert G. Statins and the risk of colorectal cancer. N Engl J Med. 2005. 352:2184–2192.
40. Yang X, So W, Ko GT, Ma RC, Kong AP, Chow CC, Tong PC, Chan JC. Independent associations between low-density lipoprotein cholesterol and cancer among patients with type 2 diabetes mellitus. CMAJ. 2008. 179:427–437.
41. Wei EK, Ma J, Pollak MN, Rifai N, Fuchs CS, Hankinson SE, Giovannucci E. C-peptide, insulin-like growth factor binding protein-1, glycosylated hemoglobin, and the risk of distal colorectal adenoma in women. Cancer Epidemiol Biomarkers Prev. 2006. 15:750–755.
TOOLS
Similar articles